AstraZeneca's (AZN) earnings are poised to see a double-digit growth in 2025 with "continued strong product sales momentum," Morgan Stanley said, initiating coverage on the Cambridge, UK-based drug manufacturer with an overweight rating and a price target of 145 pounds ($180).
Company guidance to grow earnings per share by a low double-digit percentage and revenue by a high single-digit percentage "has proven a clearing event," and "we see scope for positive earnings revisions," Morgan Stanley said Wednesday in a report.
The outlook eased investor concerns on "continued high investment spend" and Inflation Reduction Act and volume-based procurement headwinds, the report said.
AstraZeneca "uniquely" offers exposure to the multibillion-dollar markets for cancer, cardiovascular and renal antibody-drug conjugates and next-generation immuno-oncology, the report said.
Shares of the company rose 1.3% in recent Wednesday trading.
Price: 73.69, Change: +0.96, Percent Change: +1.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.